Cefepime Kabi

Leaflet accompanying the packaging: information for the user

Cefepime Kabi, 1 g, powder for solution for injection or infusion

Cefepime Kabi, 2 g, powder for solution for injection or infusion

Cefepime

Read the leaflet carefully before using the medicine, as it contains important information for the patient.

­
Keep this leaflet, you may need to read it again.
­
In case of any doubts, consult a doctor.
­
If the patient experiences any side effects, including those not listed in this leaflet, they should inform their doctor. See section 4.

Table of contents of the leaflet

• 1. What is Cefepime Kabi and what is it used for
• 2. Important information before using Cefepime Kabi
• 3. How to use Cefepime Kabi
• 4. Possible side effects
• 5. How to store Cefepime Kabi
• 6. Contents of the packaging and other information

1. What is Cefepime Kabi and what is it used for

Cefepime Kabi is an antibiotic used to treat infections of various parts of the body, caused by bacteria. It belongs to a group of antibiotics called "fourth-generation cephalosporins". Cefepime only works on certain types of bacteria, which means it is only suitable for treating certain types of infections. Cefepime Kabi is used to treat various infections:

• in adult patients and children over 12 years of age:
• complicated (severe) urinary tract and kidney infections (urinary tract infections);
• lung infections (pneumonia);
• complicated (severe) abdominal infections;
• peritonitis (inflammation of the lining of the abdominal cavity) associated with dialysis in patients undergoing continuous ambulatory peritoneal dialysis;

­
in children from 2 months to 12 years of age and weighing ≤40 kg:

• complicated (severe) urinary tract and kidney infections (urinary tract infections);
• lung infections (pneumonia).

Cefepime may be used in adult patients and children over 2 months of age to treat bacterial blood infections (bacteremia) that are or may be associated with the infections listed above. Cefepime may be used in adult patients and children over 2 months of age with neutropenia (patients with reduced immunity) and fever, if it is suspected that it is caused by a bacterial infection.

2. Important information before using Cefepime Kabi

When not to use Cefepime Kabi

• If the patient is allergic (hypersensitive) to:
• cefepime or any of the other ingredients of this medicine (listed in section 6);
• any other antibiotic from the cephalosporin group.
• If the patient has ever had a severe allergic reaction to any other antibiotic from the beta-lactam group (such as penicillins, so-called monobactams, and carbapenems).

In case of any doubts, consult a doctor.

Warnings and precautions

Before starting treatment with Cefepime Kabi, consult a doctor:

• if the patient has ever had an allergic reaction to cefepime or any other antibiotic from the beta-lactam group, or to any other medicine; if an allergic reaction occurs during treatment with cefepime, the doctor should be informed immediately, as the reaction may be severe and the doctor will immediately stop the treatment;
• if the patient has ever been diagnosed with asthma or has a tendency to allergies;
• if the patient has kidney function disorders; the dose of Cefepime Kabi may need to be adjusted;
• if severe and persistent diarrhea occurs during treatment; this may be a sign of colitis and prompt medical attention may be necessary;
• if the patient suspects that they have developed a new infection while using Cefepime Kabi; this may be an infection caused by microorganisms that are not sensitive to cefepime and it may be necessary to stop the treatment;
• if the doctor orders blood or urine tests, the patient should inform the doctor that they are using Cefepime Kabi, as this medicine may affect the results of some tests.

Cefepime Kabi and other medicines

Tell the doctor about all medicines that the patient is currently taking or has recently taken, as well as any medicines that the patient plans to take. This is important because some medicines should not be taken at the same time as cefepime. In particular, tell the doctor if the patient is taking:

• any other antibiotics, especially aminoglycosides (such as gentamicin) or diuretic medicines (such as furosemide); in such cases, kidney function should be monitored;
• medicines that prevent blood clots (anticoagulant coumarin derivatives, such as warfarin); their effect may be enhanced;
• certain types of antibiotics (bacteriostatic antibiotics), as they may affect the action of cefepime.

Pregnancy and breastfeeding

If the patient is pregnant or thinks she may be pregnant, she should inform her doctor. There is no data on the use of cefepime in pregnant women. It is recommended to avoid using cefepime in pregnant women. Small amounts of the medicine may pass into breast milk. Cefepime can be used during breastfeeding, but the baby should be closely monitored for any side effects. If the patient is pregnant or breastfeeding, thinks she may be pregnant, or plans to have a child, she should consult a doctor before using this medicine.

Driving and using machines

During treatment with Cefepime Kabi, the patient may experience headaches or seizures, dizziness, confusion, or altered state of consciousness. If such symptoms occur, the patient should not drive vehicles or operate machines.

3. How to use Cefepime Kabi

Cefepime Kabi is usually administered by a doctor or nurse. It is administered:

• by slow injection into a vein (intravenous injection) or
• by infusion (drip) into a vein (intravenous infusion). The dose depends on the type and severity of the infection, as well as the patient's age, weight, and kidney function. The doctor will provide explanations in this regard.

Cefepime Kabi is usually administered 2-3 times a day. The recommended dosage is:

• for adult patients and adolescents (over 12 years of age): 4 to 6 g per day;
• for infants and children (from 2 months to 12 years of age): 100 to 150 mg/kg body weight per day;
• the duration of treatment is usuallyfrom 7 to 10 days;
• the maximum dose for children over 2 months of age and adult patients is 6 g per day.

Using a higher dose of Cefepime Kabi than recommended

If the patient thinks they have received too much of the medicine, they should inform their doctor as soon as possible.

Missing a dose of Cefepime Kabi

If the patient thinks they have missed a dose of the medicine, they should inform their doctor.

Stopping treatment with Cefepime Kabi

This medicine should be used for the entire prescribed treatment period, even if the patient feels better after the first few doses. If the patient stops treatment too early, the infection may not be fully cured. In case of any further doubts about using this medicine, consult a doctor.

4. Possible side effects

Like all medicines, Cefepime Kabi can cause side effects, although not everybody gets them. If the following side effects occur, immediate action should be taken. If any of the following side effects occur, the patient should stopusingthe medicine and immediatelyconsult a doctor.

• Pseudomembranous colitis (or post-antibiotic colitis), causing severe, prolonged, watery diarrhea with abdominal cramps and fever (occurs in less than 1 in 100 patients).
• Severe allergic reaction (anaphylaxis) with sudden wheezing or shortness of breath, swelling of the face or body, rash, fainting (loss of consciousness) (occurs in less than 1 in 1,000 patients).
• Mild or moderate skin rash with blisters and peeling (erythema multiforme) (frequency cannot be estimated from the available data).
• Sudden onset of severe rash and swelling with blisters or peeling of the skin, associated with high fever and joint pain (Stevens-Johnson syndrome) (frequency cannot be estimated from the available data).

The following side effects have also been observed during treatment with Cefepime Kabi.

Very common side effects (more than 1 in 10 patients):

• false-positive test result for antibodies causing the death (destruction) of red blood cells.

Common side effects (less than 1 in 10 patients):

• allergic reactions, such as skin rash;
• diarrhea;
• pain, swelling, and inflammation at the injection or infusion site (phlebitis) and thrombophlebitis;
• changes in blood cell count, including low red blood cell count (anemia) and changes in the count of certain types of white blood cells;
• changes in laboratory test results, indicating liver function disorders.

Uncommon side effects (less than 1 in 100 patients):

• vaginitis;
• itching of the skin, hives;
• headache, fever;
• nausea (nausea) and vomiting;
• thrush (in the mouth);
• increased values of certain blood test results (urea and creatinine), indicating kidney function;
• changes in blood cell count (changes in the count of certain types of white blood cells and platelets);
• inflammation at the infusion site.

Rare side effects (less than 1 in 1,000 patients):

• disorders of sensation (paresthesia), confusion, dizziness, seizures, disorders of appetite;
• breathing difficulties;
• thrush;
• abdominal pain, constipation;
• vasodilation;
• chills.

Frequency not known (cannot be estimated from the available data):

• life-threatening allergic reactions (anaphylactic shock);
• changes in blood cell count, significant reduction in red blood cell count (anemia) or white blood cell count (agranulocytosis);
• brain function disorders, including altered state of consciousness (stupor, coma), confusion, hallucinations, muscle movements (myoclonic seizures);
• kidney function disorders (kidney failure, toxic nephropathy);
• gastrointestinal disorders;
• bleeding from damaged vessels (hemorrhage);
• false-positive glucose test results in urine.

Reporting side effects

If any side effects occur, including those not listed in the leaflet, the patient should inform their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products Al. Jerozolimskie 181C 02-222 Warsaw tel.: + 48 22 49 21 301 fax: + 48 22 49 21 309 e-mail: ndl@urpl.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of the medicine.

5. How to store Cefepime Kabi

The medicine should be stored out of sight and reach of children. Do not use this medicine after the expiry date stated on the packaging after EXP. The expiry date refers to the last day of the month. Do not store above 25°C. Store the vials in a carton to protect from light. The solution of Cefepime Kabi should be administered immediately after preparation. Do not administer Cefepime Kabi if the solution is cloudy and has changed color; the solution should be completely clear, colorless to amber-yellow. Unused solution should be discarded. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the packaging and other information

What Cefepime Kabi contains

• The active substance of the medicine is cefepime in the form of cefepime hydrochloride monohydrate.

Cefepime Kabi, 1 g Each vial contains 1 g of cefepime in the form of cefepime hydrochloride monohydrate (1189.2 mg). Cefepime Kabi, 2 g Each vial contains 2 g of cefepime in the form of cefepime hydrochloride monohydrate (2378.5 mg).

• The other ingredient is L-arginine.

What Cefepime Kabi looks like and contents of the pack

Cefepime Kabi, powder for solution for injection or infusion, is usually mixed with water for injections or other suitable fluids to obtain a clear solution for intravenous injection or intravenous infusion. The prepared solution of cefepime can be mixed by the doctor with other suitable infusion fluids. The packaging contains: 1 vial, 10 vials, or 50 vials.

Marketing authorization holder and manufacturer

Marketing authorization holder

Fresenius Kabi Polska Sp. z o.o. Al. Jerozolimskie 134 02-305 Warsaw

Manufacturer

Labesfal-Laboratórios Almiro S.A. (Fresenius Kabi Group) Lagedo 3465-157 Santiago de Besteiros Portugal For more information, contact the representative of the marketing authorization holder: Fresenius Kabi Polska Sp. z o.o. Al. Jerozolimskie 134 02-305 Warsaw tel.: + 48 22 345 67 89

This medicinal product is authorized in the Member States of the European Economic Area under the following names:

Belgium

Cefepim Fresenius Kabi 1 g, poeder voor oplossing voor injectie of infusie Cefepim Fresenius Kabi 2 g, poeder voor oplossing voor injectie of infusie

Bulgaria

Cefepime Kabi 1 g powder for solution for injection or infusion

Cyprus

Cefepime Kabi 1 g, κόνις για διάλυμα προς ένεση ή έγχυση Cefepime Kabi 2 g, κόνις για διάλυμα προς ένεση ή έγχυση

Greece

Cefepime Kabi 1 g, κόνις για διάλυμα προς ένεση ή έγχυση Cefepime Kabi 2 g, κόνις για διάλυμα προς ένεση ή έγχυση

Netherlands

Cefepim Fresenius Kabi 1 g, poeder voor oplossing voor injectie of infusie Cefepim Fresenius Kabi 2 g, poeder voor oplossing voor injectie of infusie

Spain

Cefepima Kabi 1g polvo para solución inyectable o para perfusión EFG Cefepima Kabi 2 g polvo para solución inyectable o para perfusión EFG

Poland

Cefepime Kabi

Portugal

Cefepima Kabi

Romania

CEFEPIME KABI 1 g, pulbere pentru soluţie injectabilă sau perfuzabilă

Slovenia

Cefepim Kabi 1 g prašek za raztopino za injiciranje ali infundiranje Cefepim Kabi 2 g prašek za raztopino za injiciranje ali infundiranje

Date of last revision of the leaflet:

---------------------------------------------------------------------------------------------------------------------------
Information intended for healthcare professionals only:
Before administration, it is recommended to check if the solution for parenteral administration does not contain visible solid particles.
During storage, the solution may change color (from colorless to amber-yellow), which does not affect the efficacy of the medicine.
Storage conditions
Before opening the vial
Do not store above 25°C.
Store the vials in a carton to protect from light.
After dissolution/dilution
The solution of cefepime should be used immediately after dissolution.
The prepared solution shows chemical and physical stability for 2 hours at 25°C.
From a microbiological point of view, the medicine should be used immediately. If it is not used immediately, the user is responsible for the storage time and conditions before use. The storage time should not exceed 24 hours at 2°C - 8°C, unless the solution was prepared in controlled and validated aseptic conditions.
Compatibility
Cefepime is compatible with the following solvents and solutions: 0.9% sodium chloride solution (with 5% glucose solution or without), 10% glucose solution, Ringer's solution (with 5% glucose solution or without), M/6 sodium lactate.
Instructions for dissolution, dilution, and administration
To administer by directintravenous injection, Cefepime Kabi should be dissolved in sterile water for injections, 5% glucose solution for injections, or 0.9% sodium chloride solution, using the volumes listed in the table "Preparation of cefepime solutions". The prepared solution should be administered by direct intravenous injection over 3 to 5 minutes or added to an infusion set when the patient is receiving a compatible infusion fluid.
To administer by infusion, prepare the solution of cefepime 1 g or 2 g as for direct intravenous injection and add the appropriate amount of the resulting solution to a container with a compatible infusion fluid. The intravenous infusion time should be 30 minutes.
Preparation of cefepime solutions

Any unused remainder of the medicine or its waste should be disposed of in accordance with local regulations.